Choosing and using non‐steroidal anti‐inflammatory drugs in haemophilia
- 4 November 2015
- journal article
- review article
- Published by Wiley in Haemophilia
- Vol. 22 (2) , 179-187
Abstract
The management of pain and inflammation in haemophilic arthropathy is challenging due to the lack of anti‐inflammatory analgesic agents perfectly suitable for this population. Non‐steroidal anti‐inflammatory drugs (NSAIDs) are widely used in the management of arthritis due to their analgesic and anti‐inflammatory effects. Their use in persons with haemophilia (PWH), however, is limited due to increased risk of bleeding mainly from the upper gastrointestinal (UGI) tract. Cyclooxygenase‐2 (COX‐2) selective NSAIDs which have comparable analgesic effect to traditional NSAIDs (tNSAIDs) but with less UGI bleeding have been considered to be a suitable option for treatment of haemophilic arthropathy. COX‐2 inhibitors, however, have an increased in the risk of cardiovascular (CV) disease. Although the atherosclerotic burden in PWH is similar to that in the general population, the risk of CV‐related deaths is lower. PWH have a higher risk of GI bleeding and lower risk of thrombotic disease compared to general population. Therefore, when PWH require anti‐inflammatory/analgesic agents, it seems reasonable to use lowest dose of COX‐2 inhibitors for the shortest period together with a proton pump inhibitor. Helicobacter pylori infection should be tested for and eradicated prior to starting NSAID treatment in PWH. Furthermore, regular blood pressure and renal function test monitoring is required during COX‐2 inhibitor treatment.Keywords
This publication has 66 references indexed in Scilit:
- Orthopaedic co‐morbidities in the elderly haemophilia population: a reviewHaemophilia, 2012
- Reduced cardiovascular mortality in hemophilia despite normal atherosclerotic loadJournal of Thrombosis and Haemostasis, 2012
- Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational StudiesPLOS Medicine, 2011
- Nonsteroidal Antiinflammatory Drug-Related Injury to the Gastrointestinal Tract: Clinical Picture, Pathogenesis, and PreventionGastroenterology Clinics of North America, 2010
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled TrialsCirculation, 2008
- Acetaminophen (paracetamol) is a selective cyclooxygenase‐2 inhibitor in manThe FASEB Journal, 2007
- Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trialsBMJ, 2006
- Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinationsGut, 2006
- Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunitiesJournal of Clinical Investigation, 2005